N/A
Completed N=100
Assessment of Novel Intraocular Injection Guide
Retinal Disease
Source: ClinicalTrials.gov NCT02315170 ↗
Enrolled (actual)
100
Serious AEs
0.0%
Results posted
May 2021
Primary outcomePrimary: Visual Analogue Scale (VAS) — 14; 33 mm on the VAS
Summary
To determine if a novel intraocular injection guide (IIG) reduces patient discomfort during and after intravitreal injections.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Visual Analogue Scale (VAS) |
14; 33 | — |
Eligibility Criteria
Inclusion Criteria
- Subjects must be receiving bilateral injections of the same dose of vascular endothelial growth factor (VEGF) inhibitor
- Injections in both eyes must be given on the same day
- Male or female age 18 years or older
Exclusion Criteria
-Any condition or reason that precludes the subject's ability to comply with the study -
Data sourced from ClinicalTrials.gov (NCT02315170). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.